IMPACT OF VTE ON HEALTHCARE FACILITIES
Mechanical Prophylaxis vs. Pharmacological Prophylaxis (anticoagulants)
There are two ways to prevent blood clots: Mechanical Prophylaxis (VenaPro) and Pharmacological prophylaxis (anticoagulants). Anticoagulants limit the blood’s ability to clot, therefore carrying a large risk of bleeding. They also should not be taken with certain foods, spices, alcohol, or other medications. Additionally, anticoagulants should not be taken until the body has achieved hemostasis after surgery (normal stoppage of blood flow after injury/surgery). This gap in coverage can take 5-24 hrs, which is a critical time for the prevention of clots. The VenaPro administers safe effective mechanical prophylaxis for the prevention of blood clots (called Deep Vein Thrombosis – DVT, or Pulmonary Embolism-PE). Mechanical prophylaxis is safe (can be used on 98% of population immediately after surgery), effective (studies show mechanical prophylaxis has equal efficacy as pharmacological), cost-effective (average cost of a blood clot prevention to Medicare is $46,709 per incident), and can be used during and immediately after surgery.
Using VenaPro for postoperative protection against DVTs and PEs can help hospitals in several ways:
Developing a blood clot while in the hospital has been deemed a Never Event (a result that a patient should be protected against). If a patient returns to the hospital with a blood clot within 30 days after a total knee or total hip procedure, Medicare will not pay for any costs to treat on that readmission. Example: A patient develops a postoperative pulmonary embolism (a blood clot that breaks away at the site of formation, travels to the lungs and blocks an artery) after a total knee surgery. The cost to treat a pulmonary embolism is $16,644, but the average hospital profit from a total knee is $1,500, so hospital would need to perform 11 total knee procedures to recover from one Never Event. VenaPro supplies mechanical prophylaxis to at-risk patients to help prevent the formation of blood clots after discharge.
Medicare reimbursement for hospitals has changed from a pay-for-reporting model to a pay-for-performance model, broadly called Value Based Purchasing (VBP). In simpler terms, hospitals will no longer receive a flat fee for providing care; now the reimbursement will be based on the outcome of the patient’s procedure/visit. Several outcome measures will be collected such as: Did the patient develop an infection? Was appropriate heart attack care given to the patient on arrival? Was blood clot prevention ordered and administered for surgical patients? In addition, the reimbursement will also be based on patient experience and satisfaction: Was my pain managed? Did I receive clear instructions at discharge? Was my hospital room clean?
VenaPro not only address the VBP outcome measure for DVTs and PEs, but also gives the patient a Continuum-of-Care after leaving the hospital. The patient is better educated on their blood clot risks and has added protection after discharge. This furthers the patient’s experience with the hospital and the care they provided.
Limit the liability of hospitals and physicians – Death caused by a hospital’s failure to prevent blood clots, especially with high-risk patients is a big concern for facilities and physicians. Blood clots kill more Americans each year than breast cancer, AIDs, and highway fatalities combined. With a trend towards shorter hospital stays, this is a large risk for patients after they are discharged from the facility. VenaPro helps protect healthcare providers by supplying needed mechanical prophylaxis when patients are not being monitored physicians and nursing staff.
For more information on VTE Guidelines, download any of the following PDF’s.
- > AAOS Summary of Recommendations
- > AORN DVT Guidelines
- > ASPS VTE Evidence Based Practices
- > Chest 20082
- > Chest 20122
- > NCCN VTE Cancer Guidelines 2011